DS
SEEL

David Shaw’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

David Shaw’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30
Closed -$276K – 5786
2021
Q3 		$276K Buy
30
+6
+25% +$51.6K ﹤0.01% 4406
2021
Q2 		$247K Buy
+24
New +$394K ﹤0.01% 4365

Other funds holding SEEL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $1.07B AUM 34.04% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

David Shaw's SEEL Position: Q4 2021 in Review

David Shaw sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2021, closing a stake of 30 shares — an estimated $276K sold.

David Shaw first reported a position in SEEL in Q2 2021 and held it in 2 quarters. The position peaked at $276K in Q3 2021. 82 funds tracked by Wall St. Rank hold SEEL as of Q4 2021.

  • David Shaw reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • David Shaw sold 30 Seelos Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $276K.
  • David Shaw first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • David Shaw's Seelos Therapeutics, Inc. Common Stock position peaked at $276K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.